Statistics from Altmetric.com
Do antiepileptic drugs (AEDs) increase the risk of self-harm and suicidal behaviour?
453 cases with self-harm or suicidal behaviour and 8962 age- and sex-matched controls identified using the UK General Practice Research Database (GPRD). Participants were identified from a cohort of 44 300 people with epilepsy or non-febrile seizures who had been treated with at least one prescription for AEDs between 1990 and 2005. The date of cohort entry was date of first AED prescription, and controls were matched with cases for year of cohort entry. The index date for cases was the date of first recorded incident of self-harm or suicidality, and an index date for controls was selected to give an equivalent length of follow-up to their matched case.
General population, UK; 1990–2005.
Use of AEDs, classified as barbiturates (phenobarbital, primidone, methylphenobarbital), conventional AEDs (carbamazepine, divalproex=valproate, phenytoin, ethosuximide, acetazolamide), newer AEDs with a low risk of causing depression in clinical trials (≤1%; oxcarbazepine, lamotrigine, gabapentin, pregabalin) or newer AEDs with a high risk of causing depression in clinical trials (>1%; levetiracetam, tiagabine, topiramate, vigabatrin). AED exposure was classified as current (prescription lasting into the 14 days before the index date), recent (prescription lasting …
Source of funding Bayer Schering Pharma.
Competing interests JLA-M has received consulting fees from Lundbeck and Risk MR. He also provided expert testimony for Sanofi-Aventis.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.